Ex Vivo Derived Primary Melanoma Cells: Implications for Immunotherapeutic Vaccines

Journal of Cancer

Volumn 4, Issue 5, 2013, Pages 371-382

  Suriano, Robert ^a   Rajoria, Shilpi ^a   George, Andrea L ^a   Geliebter, Jan ^a   Wallack, Marc ^a,b   Tiwari, Raj K ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b METROPOLITAN HOSPITAL CENTER   (United States)

Author keywords

immunotherapeutic vaccine; Melanoma cells

Indexed keywords

CD146 ANTIGEN; CD71 ANTIGEN; GLYCOPROTEIN GP 100; MELAN A; MELANOMA ANTIGEN; MELANOMA ANTIGEN 1; MELANOMA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CARCINOGENIC ACTIVITY; CELL INVASION; CELL MIGRATION; CLINICAL ARTICLE; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; MALE; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PHENOTYPE;

EID: 84883008460     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.6625     Document Type: Article

References (42)

1. Bandarchi .B.Linglei M, Navab R, et al. From Melanocyte to Metastatic Malignant Melanoma. Dermatol Res Pract. 2010; 583748.
2. Atkins MB, Hsu J, Lee S, et al. Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2008; 26:5748-5754.
3. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol. 2006; 24:4738-4745.
4. Weber J. Immunotherapy for melanoma. Curr Opin Oncol. 2011; 23:163-169.
5. Block MS, Suman VJ, Nevala WK, et al. Pilot study of granulocyte- macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine. Melanoma Res. 2011; 21:438-445.
6. McCardle TW, Messina JL, Sondak VK. Completely regressed cutaneous melanocytic lesion revisited. Semin Oncol. 2009; 36:498-503.
7. Overwijk WW and Restifo NP. Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit Rev Immunol. 2000; 20:433-450.
8. Pittet MJ, Zippelius A, Valmori D, et al. Melan-A/MART-1-specific CD8 T cells: from thymus to tumor. Trends Immunol. 2002; 23:325-328.
9. Gnjatic S, Nishikawa H, Jungbluth AA, et al. NY-ESO-1: review of an immunogenic tumor antigen. Adv Cancer Res. 2006; 95:1-30.
10. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723.
11. Flaherty KT, Yasothan U, Kirkpatrick P. Vemurafenib. Nat Rev Drug Discov. 2011; 10:811-812.
12. Boon T. Tumor antigens recognized by cytolytic T lymphocytes: present perspectives for specific immunotherapy. Int J Cancer 1993; 54:177-180.
13. Rosenberg SA. A new era of cancer immunotherapy: converting theory to performance. CA Cancer J Clin. 1999; 49:70-73.
14. Wasmeier C, Hume AN, Bolasco G, et al. Melanosomes at a glance. J Cell Sci. 2008; 121: 3995-3999.
15. Luo Y, Zheng C, Zhang J, et al. Recognition of CD146 as an ERM-binding protein offers novel mechanisms for melanoma cell migration. Oncogene. 2012; 31:306-321
16. van Muijen GN, Ruiter DJ, Hoefakker S, et al. Monoclonal antibody PAL-M1 recognizes the transferrin receptor and is a progression marker in melanocytic lesions. J Invest Dermatol. 1990;95 :65-9.
17. Roland Y, Demeule M, Fenart L, et al. Inhibition of melanoma brain metastasis by targeting melanotransferrin at the cell surface. Pigment Cell Melanoma Res. 2009; 2: 86-98
18. Gjerstorff MF, Kock K, Nielsen O, et al. MAGE-A1, GAGE and NY-ESO-1 cancer/testis antigen expression during human gonadal development. Hum Reprod. 2007; 22:953-60
19. Laduron S, Deplus R, Zhou S, et al. MAGE-A1 interacts with adaptor SKIP and the deacetylase HDAC1 to repress transcription. Nucleic Acids Res. 2004; 32:4340-4350
20. Ohnmacht GA and Marincola FM. Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma. J Cell Physiol. 2000; 182:332-338
21. Reynolds SR, Celis E, Sette A, et al. Identification of HLA-A*03, A*11 and B*07-restricted melanoma-associated peptides that are immunogenic in vivo by vaccine-induced immune response (VIIR) analysis. J Immunol Methods 2000; 244:59-67.
22. Reynolds SR, Celis E, Sette A, et al. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients. J Immunol. 1998;161: 6970-6976.
23. Reynolds SR, Oratz R, Shapiro RL, et al. Stimulation of CD8+ T cell responses to MAGE-3 and Melan A/MART-1 by immunization to a polyvalent melanoma vaccine. Int J Cancer 1997; 72:972-976.
24. Baurain J, Stas M, Hammouch F, et al. Association of primary melanoma ulceration and clinical benefit of adjuvant vaccination with tumor- specific antigenic peptides. J Clin Oncol. 2009;27:15.
25. Kruit WH, van Ojik HH, Brichard VG, et al. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer 2005;117:596-604.
26. Slingluff CL Jr, Petroni GR, Olson WC, et al. Effect of granulocyte/ macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trial. Clin Cancer Res. 2009; 15:7036-7044.
27. Filipazzi P, Pilla L, Patuzzo R, et al. Adjuvant multipeptide vaccination in high-risk early melanoma patients. J Clin Oncol. 2008; 26: 3014.
28. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011; 364:2119-2127.
29. Rajoria S, Suriano R, George A, et al. Estrogen induced metastatic modulators MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in thyroid cancer. PLoS One. 2011;6:e15879.
30. Rajoria S, Suriano R, Shanmugam A, et al. Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid. 2010; 20:33-41.
31. Barrow C, Browning J, MacGregor D, et al. Tumor antigen expression in melanoma varies according to antigen and stage Clin Cancer Res. 2006 12: 764-771.
32. Hoashi T, Watabe H, Muller J, et al. MART-1 is required for the function of the melanosomal matrix protein PMEL17/GP100 and the maturation of melanosomes. J Biol Chem. 2005; 280:14006-40016.
33. Wang RF, Appella E, Kawakami Y, et al. Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med. 1996; 184:2207-2216.
34. Robbins PF, el-Gamil M, Kawakami Y, et al. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res. 1994; 54:3124-126
35. Wang RF, Robbins PF, Kawakami Y, et al. Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med. 1995;181:799-804
36. Rajoria S, Suriano R, George AL, et al. Estrogen activity as a preventive and therapeutic target in thyroid cancer. Biomed Pharmacother. 2012; 66:151-8.
37. Tarhini AA, Leng S, Moschos SJ, et al. Safety and immunogenicity of vaccination with MART-1 (26-35, 27L), gp100 (209-217, 210M), and tyrosinase (368-376, 370D) in adjuvant with PF-3512676 and GM-CSF in metastatic melanoma. J Immunother. 2012; 35:359-366.
38. Sabbatini P, Tsuji T, Ferran L, et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin Cancer Res. 2012; 18:6497-508
39. Schaefer C, Butterfield LH, Lee S, et al. Function but not phenotype of melanoma peptide-specific CD8(+) T cells correlate with survival in a multiepitope peptide vaccine trial (ECOG 1696). Int J Cancer. 2012;131:874-84
40. Simeone E, Ascierto PA. Immunomodulating antibodies in the treatment of metastatic melanoma: the experience with anti-CTLA-4, anti-CD137, and anti-PD1. J Immunotoxicol. 2012; 9:241-7.
41. Weber J. Immunotherapy for melanoma. Curr Opin Oncol. 2011;23:163-9.
42. Rosenberg SA, Zhai Y, Yang JC, et al. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst. 1998;90:1894-900.